Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: Is it crystal clear?

Current Opinion in Rheumatology

Volumn 19, Issue 2, 2007, Pages 134-145

  Reginato, Anthony M ^a,b   Olsen, Bjorn R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ANK; Gout; Hydroxyapatite; Hyperuricemia; NALP3 inflammasome; Urate transporter 1

Indexed keywords

CALCIUM PYROPHOSPHATE; HYDROXYAPATITE; INTERLEUKIN 1 RECEPTOR; URATE;

ANTIGEN EXPRESSION; ARTHRITIS; CARTILAGE CELL; CELL DIFFERENTIATION; CRYSTAL; EXON; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETICS; GOUT; HUMAN; HYPERURICEMIA; INFLAMMATION; INNATE IMMUNITY; INTRON; KIDNEY DISEASE; MINERALIZATION; NONHUMAN; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; URIC ACID URINE LEVEL;

ANIMALS; ARTHRITIS, GOUTY; CHONDROCALCINOSIS; CRYSTALLIZATION; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYAPATITES; HYPERURICEMIA; INFLAMMATION; MICE; RENAL INSUFFICIENCY;

EID: 33846795969     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328040c00b     Document Type: Review

References (112)

1. Wu X, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A 1989; 86:9412-9416.
2. Yeldandi AV, Wang X, Alvares K, et al. Human urate oxidase gene: cloning and partial sequence analysis reveal a stop codon within the fifth exon. Biochem Biophys Res Commun 1990; 171:641-646.
3. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34:78-84.
4. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421-426.
5. Hauge M, Harvald B. Heredity in gout and hyperuricemia. Acta Med Scand 1955; 152:247-257.
6. Reed DR, Price RA. X-linkage does not account for the absence of father-son similarity in plasma uric acid concentrations. Am J Med Genet 2000; 92:142-146.
7. Emmerson BT, Nagel SL, Duffy DL, Martin NG. Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis 1992; 51:375-377.
8. Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism 2005; 54:1435-1441.
9. Chang HY, Pan WH, Yeh WT, et al. Hyperuricemia and gout in Taiwan: results fromthe nutritional Health Survey in Taiwan (1993-1996). J Rheumatol 2001; 28:1640-1646.
10. Emmerson BT. Serum urate concentrations in the Australian Aboriginal. Ann Rheum Dis 1969; 28:150-155.
11. Chan KH. Gouty arthritis in Australian Aboriginals: more common than previously suspected [letter]. Med J Aus 2004; 181:172.
12. Brauer GW. A prospective study of gout in New Zealand Maoris. Ann Rheum Dis 1978; 37:466-472.
13. Gibson T, Waterworth R, et al. Hyperuricemia, gout, and kidney function in New Zealand Maori men. Br J Rheumatol 1984; 23:276-282.
14. Prior IAM. Epidemiology of rheumatic disorders in the Pacific with particular emphasis on hyperuricemia and gout. Semin Arthritis Rheum 1981; 11:213-219.
15. Simmonds HA, McBride MB, Hatfield PJ, et al. Polynesian women are also at risk for hyperuricemia and gout because of a genetic defect in renal tubule handling. Br J Rheumatol 1994; 33:932-937.
16. Page T, Nyhan WL. The spectrum of HPRT deficiency: an update. Adv Exp Med Biol 1989; 253A:129-133.
17. Kelley WN, Rosenbloom FM, Henderson JF, Seegmiller JE. A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci USA 1967; 57:1735-1739.
18. Mateos EA, Puig JG. Purine metabolism in Lesch-Nyhan syndrome versus Kelley-Seegmiller syndrome. J Inherit Metab Dis 1994; 17:138-144.
19. Augoustides-Savvopoulou P, Papachristou F, Fairbanks LD, et al. Partial hypoxanthine-guanine phosphoribosyltransferase deficiency as the unsuspected cause of renal disease spanning three generations: a cautionary tale. Pediatrics 2002; 109:E17.
20. Ahmed M, Taylor W, Smith PR, Becker MA. Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase. J Biol Chem 1999; 274:7482-7488.
21. Chou JY, Matern D, Mansfield BC, Chen YT. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2002; 2:121-143.
22. Mineo I, Kono N, Hara N, et al. Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 1987; 317:75-80.
23. Vora S, DiMauro S, Spear D, et al. Characterization of the enzymatic defect in late-onset muscle phosphofructokinase deficiency: new subtype of glycogen storage disease type VII. J Clin Invest 1987; 80:1479-1485.
24. Seegmiller JE, Dixon RM, Kemp GJ, et al. Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1990; 87:8326-8330.
25. Bertorini TE, Shively V, Taylor B, et al. ATP degradation products after ischemic exercise: hereditary lack of phosphorylase or carnitine palmityltransferase. Neurology 1985; 35:1355-1357.
26. Sabina RL, Swain JL, Olanow CW, et al. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 1984; 73:720-730.
27. Davidson-Mundt A, Luder AS, Greene CL. Hyperuricemia in medium-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1992; 120:444-446.
28. Perheentupa J, Raivio KO. Fructose-induced hyperuricaemia. Lancet 1967; ii:528-531.
29. Hateboer N, Gumbs C, Teare MD, et al. Confirmation of a gene locus for medullary cystic kidney disease (MCKD2) on chromosome 16p12. Kidney Int 2001; 60:1233-1239.
30. Kamatani N, Moritani M, Yamanaka H, et al. Localization of a gene for familial juvenile hyperuricemic nephropathy causing underexcretion-type gout to 16p12 by genome-wide linkage analysis of a large family. Arthritis Rheum 2000; 43:925-929.
31. Hart TC, Gorry MC, Hart PS, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39:882-892.
32. Turner JJ, Stacey JM, Harding B, et al. UROMODULIN mutations cause familial juvenile hyperuricemic nephropathy. J Clin Endocrinol Metab 2003; 88:1398-1401.
33. Zager RA, Cotran RS, Hoyer JR. Pathologic localization of Tamm-Horsfall protein in interstitial deposits in renal disease. Lab Invest 1978; 38:52-57.
34. Vylet'al P, Kublova M, Kalbacova M, et al. Alterations of uromodulin biology: a common denominator of the genetically heterogeneous FJHN/MCKD syndrome. Kidney Int 2006; 70:1155-1169. Uromodulin mutations were identified in six families. Genetic defects interfere with uromodulin biology and suggest that a more appropriate term for this syndrome may be uromodulin-associated kidney diseases.
35. Bleyer AJ, Hart TC, Shihabi Z, et al. Mutations in the uromodulin gene decrease urinary excretion of Tamm-Horsfall protein. Kidney Int 2004; 66:974-977.
36. Meyer WJ 3rd, Gill JR Jr, Bartter FC. Gout as a complication of Bartter's syndrome. A possible role for alkalosis in the decreased clearance of uric acid. Ann Intern Med 1975; 83:56-59.
37. Wolf MT, Dotsch J, Konrad M, et al. Follow-up of five patients with FHHNC due to mutations in the Paracellin-1 gene. Pediatr Nephrol 2002; 17:602-608.
38. Christodoulou K, Tsingis M, Stavrou C, et al. Chromosome 1 localization of a gene for autosomal dominant medullary cystic kidney disease. Hum Mol Genet 1998; 7:905-911.
39. Stavrou C, Pierides A, Zouvani I, et al. Medullary cystic kidney disease with hyperuricemia and gout in a large Cypriot family: no allelism with nephronophthisis type 1. Am J Med Genet 1998; 77:149-154.
40. Wolf MT, Mucha BE, Hennies HC, et al. Medullary cystic kidney disease type 1: mutational analysis in 37 genes based on haplotype sharing. Hum Genet 2006; 119:649-658. Mutational analysis of all 37 positional candidate genes revealed sequence variations in three different genes, AK000210, CCT3, and SCAMP3, that segregated in each affected kindred and were not found in 96 healthy individuals, indicating that a single responsible gene causing medullary cystic kidney disease type 1 remains elusive.
41. Ohno I, Ichida K, Okabe H, et al. Familial juvenile gouty nephropathy: exclusion of 16p12 from the candidate locus. Nephron 2002; 92:573-575.
42. Hodanova K, Majewski J, Kublova M, et al. Mapping of a new candidate locus for uromodulin-associated kidney disease (UAKD) to chromosome 1q41. Kidney Int 2005; 68:1472-1482.
43. Bingham C, Ellard S, van't Hoff WG, et al. Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1beta gene mutation. Kidney Int 2003; 63:1645-1651.
44. Igarashi P, Shao X, McNally BT, Hiesberger T. Roles of HNF-1beta in kidney development and congenital cystic diseases. Kidney Int 2005; 68:1944-1947.
45. Li T, Walsh JR, Ghishan FK, Bai L. Molecular cloning and characterization of a human urate transporter (hURAT1) gene promoter. Biochim Biophys Acta 2004; 1681:53-85.
46. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447-452.
47. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15:164-173.
48. Iwai N, Mino Y, Hosoyamada M, et al. A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int 2004; 66:935-944.
49. Taniguchi A, Urano W, Yamanaka M, et al. A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 2005; 52:2576-2577.
50. Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 54:292-300. Polymorphisms in the N-terminus of the human URAT1 gene are associated with reduced renal uric acid excretion.
51. Shima Y, Teruya K, Ohta H. Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. Life Sci 2006; 79:2234-2247. A single nucleotide polymorphism in exon 4 at position rs893006 of the human URAT1 is associated with hyperuricemia.
52. Vazquez-Mellado J, Jimenez-Vaca AL, Cuevas-Covarrubias S, et al. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout. Rheumatology (Oxford) 2006; [Epub ahead of print] Five new mutations were found in the URAT1 gene associated with primary gout. All mutations were in exons 4 and 5; four were missense mutations and one was a frameshift mutation. However, renal uric acid excretion was not assessed in this Mexican cohort.
53. Wang WH, Chang SJ, Wang TN, et al. Complex segregation and linkage analysis of familial gout in Taiwanese aborigines. Arthritis Rheum 2004; 50:242-246.
54. Cheng LS, Chiang SL, Tu HP, et al. Genomewide scan for gout in taiwanese aborigines reveals linkage to chromosome 4q25. Am J Hum Genet 2004; 75:498-503.
55. Geesaman BJ, Benson E, Brewster SJ, et al. Haplotype-based identification of a microsomal transfer protein marker associated with the human lifespan. Proc Natl Acad Sci USA 2003; 100:14115-14120.
56. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78:6858-6862.
57. Rott KT, Agudelo CA. Gout. JAMA 2003; 289:2857-2860.
58. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-521.
59. Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005; 52:2936-2946.
60. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005; 174:5016-5023.
61. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 44:237-241. MSU and CPPD engage the caspase-1-activating NALP3 (also called cryopyrin) inflammasome, resulting in the production of active interleukin-1β and interleukin-18. These findings provide insight into the molecular processes underlying the inflammatory conditions of gout and pseudogout, and the pivotal role of the inflammasome in inflammatory arthritis.
62. Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116:2262-2271. Studies clearly demonstrate that interleukin-1 is essential for the MSU-induced inflammatory response requiring MyD88 through its function as an adaptor molecule in the IL-1R signaling pathway and not through other TLR receptors.
63. Boskey AL. Mineral-matrix interactions in bone and cartilage. Clin Orthop Relat Res 1992; 281:244-274.
64. Gajjeraman S, Narayanan K, Hao J, George A. Matrix macromolecules in hard tissues controls the nucleation and hierarchical assembly of hydroxyapatite. J Biol Chem. 2006; 19: epub ahead of print. Organic constituents of bones and teeth, namely type I collagen and dentin matrix protein 1, are effective crystal modulators.
65. Reginato AJ, Passano GM, Neumann G, et al. Familial spondyloepiphyseal dysplasia tarda, brachydactyly, and precocious osteoarthritis associated with an arginine 75→cysteine mutation in the procollagen type II gene in a kindred of Chiloe Islanders. I. Clinical, radiographic, and pathologic findings. Arthritis Rheum 1994; 37:1078-1088.
66. Maeda S, Ishidou Y, Koga H, et al. Functional impact of human collagen alpha2(XI) gene polymorphism in pathogenesis of ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res 2001; 16:948-957.
67. Tanaka T, Ikari K, Furushima K, et al. Genomewide linkage and linkage disequilibrium analyses identify COL6A1, on chromosome 21, as the locus for ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet 2003; 73:812-822.
68. Derfus BA, Kurian JB, Butler JJ, et al. The high prevalence of pathologic calcium crystals in preoperative knees. J Rheumatol 2002; 29:570-574.
69. Nalbant S, Martinez JA, Kitumnuaypong T, et al. Synovial fluid features and their relations to osteoarthritis severity: new findings from sequential studies. Osteoarthritis Cartilage 2003; 11:50-54.
70. Neogi T, Nevitt M, Niu J, et al. Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum 2006; 54:1822-1828. In knees with osteoarthritis, the presence of chondrocalcinosis was not associated with increased cartilage loss as assessed by MRI.
71. Baldwin CT, Farrer LA, Adair R, et al. Linkage of early-onset osteoarthritis and chondrocalcinosis to human chromosome 8q. Am J Hum Genet 1995; 56:692-697.
72. Hughes AE, McGibbon D, Woodward E, et al. Localisation of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 1995; 4:1225-1228.
73. Pendleton A, Johnson MD, Hughes A, et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002; 71:933-940.
74. Williams CJ, Zhang Y, Timms A, et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002; 71:985-991.
75. Williams CJ, Pendleton A, Bonavita G, et al. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2003; 48:2627-2631.
76. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289:265-270.
77. Zhang Y, Johnson K, Russell RG, et al. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5′-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum 2005; 52:1110-1117.
78. Zaka R, Stokes D, Dion AS, et al. P5L mutation in Ank results in an increase in extracellular inorganic pyrophosphate during proliferation and nonmineralizing hypertrophy in stably transduced ATDC5 cells. Arthritis Res Ther 2006; 8; [Epub ahead of print] This study confirmed a gain-of-function mutation in the P5L Ank mutant with respect to ePPi elaboration, but the effect is modified by high levels of expression of alkaline phosphatase in ATDC5 cells during hypertrophy and terminal differentiation, resulting in the deposition of BCP crystals.
79. Zhang Y, Brown MA, Peach C, et al. Investigation of the role of ENPP1 and TNAP genes in chondrocalcinosis. Rheumatology (Oxford) 2006 [Epub ahead of print] Polymorphisms of ENPP1 and tissue nonspecific alkaline phosphatase (TNAP) are not major determinants of susceptibility in 128 sporadic Caucasian CPPD patients from the UK.
80. Tsui FW, Tsui HW, Cheng EY, et al. Novel genetic markers in the 50-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 2003; 48:791-797.
81. Tsui HW, Inman RD, Paterson AD, et al. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 2005; 7:R513-R525.
82. Timms AE, Zhang Y, Bradbury L, et al. Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 2003; 48:2898-2902.
83. Reichenberger E, Tiziani V, Watanabe S, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 2001; 68:1321-1326.
84. Nurnberg P, Thiele H, Chandler D, et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001; 28:37-41.
85. Malkin I, Dahm S, Suk A, et al. Association of ANKH gene polymorphisms with radiographic hand bone size and geometry in a Chuvasha population. Bone 2005; 36:365-373.
86. Ali SY, Sajdera SW, Anderson HC. Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage. Proc Natl Acad Sci USA 1970; 67:1513-1520.
87. Akisaka T, Kawaguchi H, Subita GP, et al. Ultrastructure of matrix vesicles in chick growth plate as revealed by quick freezing and freeze substitution. Calcif Tissue Int 1988; 42:383-393.
88. Terkeltaub RA. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 2001; 281:C1-C11.
89. Hirose J, Ryan LM, Masuda I. Up-regulated expression of cartilage intermediate-layer protein and ANK in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2002; 46:3218-3329.
90. Johnson K, Terkeltaub R. Upregulated ank expression in osteoarthritis can promote both chondrocyte MMP-13 expression and calcification via chondrocyte extracellular PPi excess. Osteoarthritis Cartilage 2004; 12:321-335.
91. Moss DW, Eaton RH, Smith JK, Whitby LG. Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J 1967; 102:53-57.
92. Terkeltaub R, Rosenbach M, Fong F, Goding J. Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum 1994; 37:934-941.
93. Fedde KN, Blair L, Silverstein J, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 1999; 14:2015-2026.
94. Henthorn PS, Raducha M, Fedde KN, et al. Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia. Proc Natl Acad Sci USA 1992; 89:9924-9928.
95. Okawa A, Nakamura I, Goto S, et al. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998; 19:271-273.
96. Hessle L, Johnson KA, Anderson HC, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 2002; 99:9445-9449.
97. Ono M, Russell WJ, Kudo S, et al. Ossification of the thoracic posterior longitudinal ligament in a fixed population. Radiological and neurological manifestations. Radiology 1982; 143:469-474.
98. Johnson K, Goding J, Van Etten D, et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003; 18:994-1004.
99. Harmey D, Hessle L, Narisawa S, et al. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164:1199-1209.
100. Anderson HC, Harmey D, Camacho NP, et al. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol 2005; 166:1711-1720.
101. El-Maadawy S, Kaartinen MT, Schinke T, et al. Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res 2003; 44 (Suppl 1):272-278.
102. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579-581.
103. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390.
104. Frishberg Y, Topaz O, Bergman R, et al. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med 2005; 83:33-38.
105. Topaz O, Indelman M, Chefetz I, et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet 2006; 79:759-764. SAMD9 is involved in the regulation of extraosseous calcification, a process of considerable importance in a wide range of diseases as common as atherosclerosis and autoimmune disorders.
106. Harmey D, Johnson KA, Zelken J, et al. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res 2006; 21:1377-1386. Regulation of hydroxyapatite deposition requires the coordinated actions of both pyrophosphate and osteopontin and are closely linked counterregulatory mechanisms in mineralization.
107. Kizawa H, Kou I, Iida A, et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet 2005; 37:138-144.
108. Serra R, Johnson M, Filvaroff EH, et al. Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997; 139:541-552.
109. Drissi H, Zuscik M, Rosier R, O'Keefe R. Transcriptional regulation of chondrocyte maturation: potential involvement of transcription factors in OA pathogenesis. Mol Aspects Med 2005; 26:169-179.
110. Cecil DL, Johnson K, Rediske J, et al. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol 2005; 175:8296-8302.
111. Marcos JC, De Benyacar MA, Garcia-Morteo O, et al. Idiopathic familial chondrocalcinosis due to apatite crystal deposition. Am J Med 1981; 71:557-564.
112. Pons-Estel BA, Gimenez C, Sacnun M, et al. Familial osteoarthritis and Milwaukee shoulder associated with calcium pyrophosphate and apatite crystal deposition. J Rheumatol 2000; 27:471-480.